MAUD-T2D trial: Patients with T2D and markers of more severe AUD, comparing newer GLP-1 RAs to FDA-approved medications for AUD (MAUD: acamprosate, disulfiram, or naltrexone)
Alternative Options: Brand-Name Through Insurance: Work with insurance to access Wegovy or Ozempic Local Compounding Pharmacy: Some local compounding pharmacies compound semaglutide with a prescription from your doctor Clinical Trials: Research studies may provide access Manufacturer Programs: Patient assistance programs for brand-name medications Regulatory Changes to Watch: Compounded medication availability can change based on: FDA shortage list updates (if semaglutide is removed from shortage list, compounding may become restricted) State law changes affecting telemedicine or compounding New federal regulations on compounding DEA or FDA enforcement actions Legitimate providers will notify patients of any regulatory changes affecting their ability to provide compounded semaglutide
Wegovy is available in prefilled single-dose pens with doses of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg
Studies have shown that this treatment can reduce the risk of heart disease, stroke, and other chronic health conditions
High costs serve as barrier to care High out-of-pocket costs for people without insurance coverage remain a key factor in determining who can benefit from GLP-1 medications and who cannot, said Tracy Svenyach, PhD, director of policy strategy and alliance at the Obesity Action Coalition
A similar decrease in the risk of tobacco use-related health encounters was observed for individuals without obesity diagnoses